Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial

NCT04442984 is registered in ClinicalTrials.gov with Blokhin's Russian Cancer Research Center as lead sponsor.

NCT NCT04442984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04442984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial
Lead sponsor
Blokhin's Russian Cancer Research Center
Phase
Phase 2
Overall status
Unknown status
Start date
November 3, 2019
Completion date
November 3, 2024
Enrollment
326 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophagogastric junction adenocarcinoma stage iv, gastric carcinoma stage iv